Somatostatin Or Derivative Patents (Class 514/11.1)
  • Patent number: 11370822
    Abstract: The present disclosure relates to bioactive self-assembling peptides, nanofibers and hydrogels for activating human mast cells. The peptides, nanofibers and hydrogels comprise a self-assembling peptide that mediates self-assembly linked to a MrgX2 agonist peptide; for example, (RADA)4 linked to proadrenomedullin-12 (PAMP-12).
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 28, 2022
    Assignees: The Governors of the University of Alberta, National Research Council of Canada
    Inventors: Larry D. Unsworth, Lei Lu, Marianna Kulka
  • Patent number: 11279732
    Abstract: The present invention is directed to somatostatin receptor antagonist compounds having the structure of Formula I, compositions comprising the same, and methods of using such compounds and compositions. The compounds may be useful in the prevention or treatment of hypoglycemia.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: March 22, 2022
    Assignee: CDRD VENTURES INC.
    Inventors: Stephen Paul Arns, James Brian Jaquith, Davy Jérémy Baudelet, Eric Roy Simonson, Richard Tom Liggins, Nag Sharwan Kumar, Tom Han Hsiao Hsieh
  • Patent number: 11261215
    Abstract: The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 1, 2022
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Amnon Hoffman, Chaim Gilon, Adi Klinger, Johnny Naoum
  • Patent number: 10954287
    Abstract: The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 23, 2021
    Assignee: RA PHARMACEUTICALS, INC.
    Inventors: Kristopher Josephson, Zhong Ma, Yili Sun, Nathan Ezekiel Nims, Kathleen Seyb, Sylvia Tobe, Ping Ye, Douangsone D. Vadysirisack, Guo-Qing Tang, Douglas A. Treco
  • Patent number: 10512669
    Abstract: Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a ?-defensin, analog or derivative thereof. Inventive methods include researching ?-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-?)-converting enzyme (TACE) or other proinflammatory proteases, and/or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: December 24, 2019
    Assignee: The Regents of the University of California
    Inventors: Michael E. Selsted, Dat Q. Tran
  • Patent number: 10413594
    Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: September 17, 2019
    Assignee: ProLynx LLC
    Inventors: Eric L. Schneider, Brian Hearn, Gary W. Ashley, Daniel V. Santi
  • Patent number: 10357567
    Abstract: A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 23, 2019
    Assignee: DUSA Pharmaceuticals, Inc.
    Inventors: Scott Lundahl, Michael Guttadauro
  • Patent number: 9867864
    Abstract: The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the control of hypoglycemia.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: January 16, 2018
    Assignee: Novartis AG
    Inventor: Herbert Schmid
  • Patent number: 9724394
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as an active ingredient. The neuropeptide Y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a Y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent. When a haematopoietic stem cell is released into the blood, the number of osteoclasts which induce an osteoporotic lesion by differentiation from the haematopoietic stem cell decreases, and thus progression of a bone erosion caused by osteoclasts can be prevented. Accordingly, the neuropeptide Y which is an active ingredient of the composition of the present invention is useful as a therapeutic agent for osteoporosis.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: August 8, 2017
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATION
    Inventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park, Jong Kil Lee
  • Patent number: 9650420
    Abstract: The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell. Furthermore, the present disclosure relates to a composition for preventing or treating bone diseases, including the novel peptide. The novel peptide according to the present disclosure induces mobilization of hematopoietic stem cells to blood and causes a decrease in the number of osteoclasts, and, thus, decreases bone erosion caused by osteoclasts, thereby suppressing progress of an osteoporotic lesion. Further, the novel peptide is safe since it does not cause rejection in the body. Furthermore, since the novel peptide is formed of 15 short amino acids, a low dose of the peptide can relieve symptoms of osteoporosis.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 16, 2017
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
  • Patent number: 9580466
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: February 28, 2017
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Patent number: 9446134
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example octreotide or variant thereof.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: September 20, 2016
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Patent number: 9409945
    Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a ?bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a ?bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a ?bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; and where part (T) is a —Y-L-Z— radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: August 9, 2016
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Pierre Deslongchamps, Yves Dory, Gilles Berthiaume, Luc Ouellet, Ruoxi Lan
  • Patent number: 9266924
    Abstract: The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa1 to Xaa4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a detectable label; or ii) a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins and combinations thereof, with the proviso that -L-Ar-D does not comprise a 18F-benzoyl residue.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: February 23, 2016
    Assignee: TECHNISCHE UNIVERSITÄT MÜNCHEN
    Inventors: Oliver Demmer, Horst Kessler, Hans-Jürgen Wester, Margret Schottelius, Ingrid Dijkgraaf, Andreas Konard Buck
  • Patent number: 9149510
    Abstract: The present invention relates to a combination of two or more Somatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- or SRIF-analogs) which have different selectivity for the five human somatostatin receptor subtypes, the use of such combination in the treatment of a disease mediated by activation of somatostatin receptors, and to pharmaceutical compositions comprising such a combination.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 6, 2015
    Assignee: Novartis AG
    Inventor: Herbert Schmid
  • Publication number: 20150148294
    Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Applicant: Novartis AG
    Inventors: Peter Wayne Marks, David Lebwohl
  • Patent number: 9040482
    Abstract: The present invention relates to novel octapeptide compounds of general formula (I), R-AA1-cyclo(AA2-Tyr3-D-Trp4-AA5-Val6-Cys7)-Thr8-NH2??(I) As these products have a good affinity for certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) of the somatostatin receptors is (are) involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: May 26, 2015
    Assignees: IPSEN PHARMA S.A.S., COMMISSARIAT A L'ENERGIE ATOMIQUE (C.E.A.), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Jean-Christophe Cintrat, Melinda Ligeti, Bernard Rousseau, Franck Artzner, Christophe Tarabout, Marie-Thérèse Paternostre, Nicolas Fay, Roland Cherif-Cheikh, Céline Valery
  • Publication number: 20150141338
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 8999390
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 7, 2015
    Assignee: Novartis AG
    Inventors: Holger Petersen, Markus Ahlheim
  • Publication number: 20150087588
    Abstract: The present invention relates to a combination which comprises (a) a somatostatin analogue and (b) a 11beta-hydroxylase inhibitor; each in free form or in the form of a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of diseases associated with increased stress hormone levels; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.
    Type: Application
    Filed: April 10, 2013
    Publication date: March 26, 2015
    Applicant: Novatis AG
    Inventors: Germo Hans Gericke, Herbert Anton Schmid, Mario Roberto Maldonado Lutomirsky, Li Li
  • Publication number: 20150064118
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 5, 2015
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Patent number: 8952128
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: February 10, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
  • Publication number: 20150038414
    Abstract: A pharmacutical composition for parenteral administration of a somatostatin analogue salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid.
    Type: Application
    Filed: April 30, 2014
    Publication date: February 5, 2015
    Applicant: Novartis AG
    Inventor: Olivier Jean Lambert
  • Publication number: 20150037420
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Novartis AG
    Inventors: Holger Petersen, Markus Ahlheim
  • Patent number: 8946154
    Abstract: Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: February 3, 2015
    Assignee: BCN Peptides, S.A.
    Inventors: Antonio Parente Dueña, Berta Ponsati Obiols, Jimena Fernández Carneado, Marc Gómez Caminals, Ribera Jordana I Lluch
  • Patent number: 8937152
    Abstract: Cyclohexapeptides of formula (I): as defined herein. The cyclohexapeptides are non-selective functional analogs of somatostatin.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: January 20, 2015
    Assignee: Italfarmaco SpA
    Inventors: Andrea Vitali, Massimo Pinori, Paolo Mascagni
  • Publication number: 20150004196
    Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.
    Type: Application
    Filed: June 5, 2014
    Publication date: January 1, 2015
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20140348903
    Abstract: The present invention relates to compositions forming a low viscosity mixture of: a. at least one diacyl glycerol and/or at least one tocopherol; b. at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein optionally at least one bioactive agent is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 27, 2014
    Inventors: Fredrik Tiberg, Markus Johnsson
  • Publication number: 20140349937
    Abstract: Therapeutic methods for treating a subject with benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I) to reduce the amount of prostatic hyperplastic tissue in the subject are described herein.
    Type: Application
    Filed: June 9, 2014
    Publication date: November 27, 2014
    Inventors: David L. Kleinberg, Sergio Vidal, Weifeng Ruan
  • Publication number: 20140336116
    Abstract: [Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid.
    Type: Application
    Filed: September 3, 2012
    Publication date: November 13, 2014
    Applicant: Glytech, Inc.
    Inventors: Hirofumi Ochiai, Taiji Shimoda, Kazuhiro Fukae, Masatoshi Maeda, Kazuyuki Ishii, Kenta Yoshida, Katsunari Tezuka, Keisuke Tazuru
  • Publication number: 20140329749
    Abstract: The present invention relates to compositions forming a low viscosity mixture of: a. 25-55 wt. % of at least one diacyl glycerol and/or at least one tocopherol; b. 25-55 wt. % of at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. 5-25 wt. % of at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein 0.1-10 wt. % of at least one peptide active agent comprising at least one somatostatin receptor agonist is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 6, 2014
    Inventors: Fredrik Tiberg, Markus Johnsson
  • Publication number: 20140328863
    Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 6, 2014
    Applicant: University of Southern California
    Inventor: Valter LONGO
  • Patent number: 8871712
    Abstract: Pre-formulations of a low viscosity mixture containing: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one somatostatin analog are described. The pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The pre-formulations are useful for generating depot composition far the controlled release of somatostatin analogs such as octreotide. Methods of treatment comprising the administration of such formulations are also provided, as are pre-filled administration devices and kits containing the formulations.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: October 28, 2014
    Assignee: Camurus AB
    Inventors: Fredrik Joabsson, Markus Johnsson, Andreas Norlin, Fredrik Tiberg
  • Publication number: 20140314853
    Abstract: A new microsphere formulation (composition) for controlled- or sustained-release delivery of therapeutic ingredient(s), mainly peptides and proteins not over 10K in molecular weight, comprises at least a therapeutic ingredient, a helping agent (such as PH sensitive agent whose solubility is a function of pH) and a biodegradable polymer. The therapeutic ingredient(s) and the helping agent are in the form of fine particles, less than 1O um in diameter, encapsulated in the polymer which forms the microsphere matrix. A method for preparing the composition comprises a step of in-situ precipitating the therapeutic ingredient(s) and the helping agent to the fine particles and successive steps for forming the microspheres. Such a microsphere formulation offers a well-controlled release profile for prolonged period and encapsulation efficiency over 95%.
    Type: Application
    Filed: December 5, 2012
    Publication date: October 23, 2014
    Inventors: Tuo Jin, Zhenhua Hu, Weien Yuan
  • Publication number: 20140314670
    Abstract: The invention relate to the new conjugated somatostatin analogs of formula (I), wherein A- is H or TAG-B—, wherein —B— is 0 or a spacer, wherein TAG is a chelating agent (e.g. DOTA), a fluorescent dye, (e.g. Bodipy-B derivative, a Rho-damine-B derivative, a Fluorescein-B derivative, a Cyanine-B derivative, a Porphyrin-B derivative), a bimodal agent, or a cytotoxic agent (e.g. a doxorubicin derivative) wherein R1 is CI-C4 alkynyl radical when R2 is CI-C4 azido radical and viceversa and methods for preparing same, pharmaceutical compositions comprising them and their use in imaging and the treatment of cancer.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 23, 2014
    Inventors: Débora D'Addona, Claire Bernhard, Anna Maria Rovero, Franck Denat, Michael Chorev
  • Publication number: 20140315800
    Abstract: [Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analogue thereof being replaced by glycosylated amino acids.
    Type: Application
    Filed: September 3, 2012
    Publication date: October 23, 2014
    Applicant: Glytech, Inc.
    Inventors: Hirofumi Ochiai, Taiji Shimoda, Kazuhiro Fukae, Masatoshi Maeda, Keisuke Tazuru, Kenta Yoshida
  • Publication number: 20140296144
    Abstract: The present invention relates to an improved process for large scale production of Octreotide acetate. The invention also relates to pharmaceutical composition of octreotide acetate.
    Type: Application
    Filed: September 28, 2012
    Publication date: October 2, 2014
    Inventors: Ananda Kuppanna, Mallikarjuna Sarma Dokka, Sreelatha Vanjivaka, Maria Bhaskar Reddy Komma Reddy, Bulliraju Kamana
  • Publication number: 20140286931
    Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventor: Chengzhi Zhang
  • Patent number: 8822442
    Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: September 2, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
  • Publication number: 20140242153
    Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 28, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
  • Publication number: 20140200516
    Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II; aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: ABBOTT LABORATORIES
    Inventor: Harry A. DUGGER, III
  • Publication number: 20140193347
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 4, 2013
    Publication date: July 10, 2014
    Applicant: CAMURUS AB
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
  • Publication number: 20140171368
    Abstract: The subject-matter of the present invention are nanocomplexes of polyanions and cationic peptides which are, e.g., suitable for the transport of drugs into cells and their controlled release in the organism, as well as a complex material in which the nanocomplexes are bonded to a biologically active unit for the selective recognition of tissues, cells or organelles.
    Type: Application
    Filed: August 7, 2012
    Publication date: June 19, 2014
    Applicant: UNIVERSITAET REGENSBURG
    Inventors: Achim Goepferich, Matthias Ferstl
  • Patent number: 8709998
    Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: April 29, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
  • Publication number: 20140105824
    Abstract: Provided herein are diagnostic methods for identifying subjects susceptible to treatment with a hypoxia-activated agent, and related methods. Also provided herein are methods of monitoring treatments with anti-hyaluronan agents, and related methods.
    Type: Application
    Filed: October 16, 2013
    Publication date: April 17, 2014
    Inventors: H. Michael Shepard, Xiaoming Li, Curtis Thompson
  • Publication number: 20140045752
    Abstract: Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition.
    Type: Application
    Filed: February 16, 2012
    Publication date: February 13, 2014
    Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: David H. Coy, Linchun Sun
  • Publication number: 20140031288
    Abstract: The invention describes a pharmaceutical composition comprising at least compound selected from the group of demethylating agents and HDAC inhibitors and at least one somatostatin analog or dopamine agonist for the treatment of a tumor which expresses a somatostatin and/or dopamine receptor.
    Type: Application
    Filed: October 2, 2013
    Publication date: January 30, 2014
    Applicant: Erasmus University Medical Center
    Inventor: Leendert Johannes HOFLAND
  • Patent number: 8629103
    Abstract: The present invention relates generally to the treatment of non-proliferative cystic disease of the breast. More particularly, the present invention relates generally to the treatment of non-proliferative cystic disease of the breast in BRCA1 mutant carriers. Accordingly, the invention relates to the use and application of compounds or agents, including somatostatin analogs, that inhibit insulin-like growth factor I (IGF-I) or insulin-like growth factor I receptor signaling for the treatment of non-proliferative cystic disease of the breast. The invention further relates to the use and application of these compounds or agents for the treatment of non-proliferative cystic disease of the breast in BRCA1 patients. The invention also relates to use of somatostatin analog SOM230 in treatment of non-proliferative cystic disease of the breast and more particularly, to use of somatostatin analog SOM230 in treatment of BRCA1 associated non-proliferative cystic disease.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: January 14, 2014
    Assignee: New York University
    Inventor: David L. Kleinberg
  • Publication number: 20130331319
    Abstract: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 12, 2013
    Inventors: Nicholas V. Perricone, Chim Potini